BIRC5 was somewhat downregulated in patients with DNMT3A-mutant and DNMT3A-like T-ALL when treated with either DEX or RUX alone, but dramatically suppressed by the combination therapy, a trend not observed in patient samples without DNMT3A mutations (Figure 6F). This evidence concerns the gene BIRC5 and acute lymphoblastic leukemia.